Android app Apple app link

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer

By Yahoo! Finance   |   2 weeks ago
Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer

Compass Therapeutics announced positive topline data from the COMPANION-002 trial for tovecimig in treating biliary tract cancer. The study is ongoing, with results for secondary measures expected in Q4 2025. Safety profile remains consistent, with detailed data to be reported later.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.